Anwulignan Alleviates Bone Cancer Pain by Modulating the PPARα / CXCR2 Signaling Pathway in the Rat Spinal Cord
CNS Neuroscience & Therapeutics · 2025-03 · 31 (3)
DOI: 10.1111/cns.70302 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 13.03.2025. Verfasst von Yueliang Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Bone Neoplasms, Cancer Pain, Signal Transduction, PPAR alpha. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Scientific Research Projects of Universities in Henan Province, International Science and Technology cooperation Project of Henan Province of China, Medical Science and Technology Project of Henan province.
Abstract (Originalsprache)
Aims
Advanced cancer patients frequently endure severe pain from bone metastases, and few effective treatments for bone cancer pain (BCP) exist. Although Anwulignan is known for its antioxidant, anti‐inflammatory, and antitumor properties, its effects on BCP remain unclear. This study aims to explore the analgesic effects and mechanisms of Anwulignan on bone cancer pain.
Methods
Western blotting and immunofluorescence assessed molecular expression and localization. X‐ray, micro‐CT, TRAP, and ALP staining examined bone destruction in rats. MTT, colony formation assays, and in vivo imaging analyzed tumor changes. RNA‐Seq identified differentially expressed genes, validated by ChIP analysis.
Results
Here, we showed that Anwulignan alleviated mechanical, thermal, and cold hypersensitivity and spontaneous pain, prevented bone destruction, and suppressed local tumor growth in rats with BCP. Furthermore, Anwulignan was firmly bound to proliferator‐activated receptor alpha (PPARα), increasing its thermal stability. Intrathecal (i.t.) injection of PPARα siRNA increased pain sensitivity in naive rats, and PPARα siRNA abrogated the analgesic effect of Anwulignan in BCP model rats. Moreover, the PPARα agonist pirinixic acid reduced BCP hypersensitivity and abrogated the upregulation of CXC chemokine receptor 2 (CXCR2). Importantly, PPARα bound to the CXCR2 promoter region, and Anwulignan could reverse the reduced binding of PPARα to CXCR2 caused by BCP.
Conclusion
Taken together, these results indicate that Anwulignan is a potential antitumor and analgesic agent that exerts its effects via upregulation of PPARα expression to inhibit the expression of CXCR2 and could be used for treating BCP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pain Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Department of Neuropharmacology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
- College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
- Department of Human Anatomy, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province, China.
- Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
- Institute of Neuroscience, Zhengzhou University, Zhengzhou, Henan Province, China.
ORCID-Profile: Jian Wang, Jingjing Yuan, Xiaochong Fan
Förderung
- Key Scientific Research Projects of Universities in Henan Province
- International Science and Technology cooperation Project of Henan Province of China
- Medical Science and Technology Project of Henan province
- National Basic Research (973) Program of the Ministry of Science and Technology of China
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Liu, Q., Jiang, Y., Mao, L., Zoubaa, M., Wang, J., Bu, H., Ma, M., Yuan, J., Cao, J., & Fan, X. (2025). Anwulignan Alleviates Bone Cancer Pain by Modulating the PPARα / CXCR2 Signaling Pathway in the Rat Spinal Cord. CNS Neuroscience & Therapeutics, 31(3). https://doi.org/10.1111/cns.70302
Vancouver
Wang Y, Liu Q, Jiang Y, Mao L, Zoubaa M, Wang J, et al. Anwulignan Alleviates Bone Cancer Pain by Modulating the PPARα / CXCR2 Signaling Pathway in the Rat Spinal Cord. CNS Neuroscience & Therapeutics. 2025;31(3). doi:10.1111/cns.70302
BibTeX
@article{Wang2025,
author = {Wang, Yueliang and Liu, Qingying and Jiang, Yingying and Mao, Longfei and Zoubaa, Mohamed and Wang, Jian and Bu, Huilian and Ma, Minyu and Yuan, Jingjing and Cao, Jing and Fan, Xiaochong},
title = {Anwulignan Alleviates Bone Cancer Pain by Modulating the PPARα / CXCR2 Signaling Pathway in the Rat Spinal Cord},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
volume = {31},
number = {3},
doi = {10.1111/cns.70302}
}
EUVIMED